• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与染色体微阵列相比,儿科全基因组测序的护理和成本后果。

Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray.

机构信息

Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada.

Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Canada.

出版信息

Eur J Hum Genet. 2017 Dec;25(12):1303-1312. doi: 10.1038/s41431-017-0020-3. Epub 2017 Nov 20.

DOI:10.1038/s41431-017-0020-3
PMID:29158552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5865210/
Abstract

The clinical use of whole-genome sequencing (WGS) is expected to alter pediatric medical management. The study aimed to describe the type and cost of healthcare activities following pediatric WGS compared to chromosome microarray (CMA). Healthcare activities prompted by WGS and CMA were ascertained for 101 children with developmental delay over 1 year. Activities following receipt of non-diagnostic CMA were compared to WGS diagnostic and non-diagnostic results. Activities were costed in 2016 Canadian dollars (CDN). Ongoing care accounted for 88.6% of post-test activities. The mean number of lab tests was greater following CMA than WGS (0.55 vs. 0.09; p = 0.007). The mean number of specialist visits was greater following WGS than CMA (0.41 vs. 0; p = 0.016). WGS results (diagnostic vs. non-diagnostic) modified the effect of test type on mean number of activities (p < 0.001). The cost of activities prompted by diagnostic WGS exceeded $557CDN for 10% of cases. In complex pediatric care, CMA prompted additional diagnostic investigations while WGS prompted tailored care guided by genotypic variants. Costs for prompted activities were low for the majority and constitute a small proportion of total test costs. Optimal use of WGS depends on robust evaluation of downstream care and cost consequences.

摘要

全基因组测序(WGS)的临床应用有望改变儿科医疗管理模式。本研究旨在描述与染色体微阵列(CMA)相比,儿科 WGS 后医疗保健活动的类型和成本。对 101 例发育迟缓超过 1 年的儿童进行了 WGS 和 CMA 后医疗保健活动的确定。比较了非诊断性 CMA 与 WGS 诊断和非诊断结果后的活动。活动成本以 2016 年加元(CDN)计算。在测试后,持续护理占后续活动的 88.6%。与 WGS 相比,CMA 后实验室检测的平均数量更多(0.55 比 0.09;p=0.007)。与 CMA 相比,WGS 后专科就诊的平均次数更多(0.41 比 0;p=0.016)。WGS 结果(诊断与非诊断)改变了测试类型对平均活动数量的影响(p<0.001)。诊断性 WGS 引发的活动费用超过 557 加元的病例占 10%。在复杂的儿科护理中,CMA 引发了额外的诊断性检查,而 WGS 则根据基因型变异引发了针对性的护理。大多数情况下,引发活动的成本较低,占总测试成本的一小部分。WGS 的最佳使用取决于对下游护理和成本后果的有力评估。

相似文献

1
Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray.与染色体微阵列相比,儿科全基因组测序的护理和成本后果。
Eur J Hum Genet. 2017 Dec;25(12):1303-1312. doi: 10.1038/s41431-017-0020-3. Epub 2017 Nov 20.
2
Cost-effectiveness of Genome and Exome Sequencing in Children Diagnosed with Autism Spectrum Disorder.基因组和外显子组测序在诊断自闭症谱系障碍儿童中的成本效益。
Appl Health Econ Health Policy. 2018 Aug;16(4):481-493. doi: 10.1007/s40258-018-0390-x.
3
Low-pass whole genome sequencing as a cost-effective alternative to chromosomal microarray analysis for low- and middle-income countries.高通量全基因组测序作为一种具有成本效益的替代方法,可用于中低收入国家,替代染色体微阵列分析。
Am J Med Genet A. 2024 Nov;194(11):e63802. doi: 10.1002/ajmg.a.63802. Epub 2024 Jun 25.
4
The cost-effectiveness of whole genome sequencing in neurodevelopmental disorders.全基因组测序在神经发育障碍中的成本效益。
Sci Rep. 2023 Apr 27;13(1):6904. doi: 10.1038/s41598-023-33787-8.
5
Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing.肿瘤学中的微成本诊断:从单基因检测到全基因组测序。
Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):413-414. doi: 10.1080/14737167.2021.1917385. Epub 2021 May 6.
6
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing.瑞典急性白血病基因诊断的微成本分析:从标准护理到全基因组测序。
J Med Econ. 2024 Jan-Dec;27(1):1053-1060. doi: 10.1080/13696998.2024.2387515. Epub 2024 Aug 8.
7
Bayesian cost-effectiveness analysis of Whole genome sequencing versus Whole exome sequencing in a pediatric population with suspected genetic disorders.贝叶斯成本效果分析全基因组测序与全外显子组测序在疑似遗传疾病的儿科人群中的应用。
Eur J Health Econ. 2024 Aug;25(6):999-1011. doi: 10.1007/s10198-023-01644-0. Epub 2023 Nov 17.
8
A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder.自闭症谱系障碍临床基因组检测策略的微成本和成本后果分析。
Genet Med. 2017 Nov;19(11):1268-1275. doi: 10.1038/gim.2017.47. Epub 2017 May 4.
9
From cytogenetics to cytogenomics: whole-genome sequencing as a first-line test comprehensively captures the diverse spectrum of disease-causing genetic variation underlying intellectual disability.从细胞遗传学到细胞基因组学:全基因组测序作为一线检测手段,全面捕捉到导致智力障碍的遗传变异的多样谱。
Genome Med. 2019 Nov 7;11(1):68. doi: 10.1186/s13073-019-0675-1.
10
Whole Genome Sequencing in the Evaluation of Fetal Structural Anomalies: A Parallel Test with Chromosomal Microarray Plus Whole Exome Sequencing.全基因组测序在胎儿结构畸形评估中的应用:染色体微阵列联合全外显子组测序的平行检测。
Genes (Basel). 2021 Mar 6;12(3):376. doi: 10.3390/genes12030376.

引用本文的文献

1
TRIAGE-GS: protocol for a randomised controlled trial of a genomics-first approach to rare disease diagnosis for patients awaiting assessment by a clinical geneticist.TRIAGE-GS:针对等待临床遗传学家评估的患者,采用基因组学优先方法进行罕见病诊断的随机对照试验方案。
BMJ Open. 2025 Aug 10;15(8):e107603. doi: 10.1136/bmjopen-2025-107603.
2
Genetic Test Utilization and Cost among Families of Children Evaluated for Genetic Conditions: An Analysis of USA Commercial Claims Data.接受遗传疾病评估儿童家庭的基因检测应用情况及费用:基于美国商业索赔数据的分析
Appl Health Econ Health Policy. 2025 May;23(3):519-530. doi: 10.1007/s40258-024-00942-9. Epub 2025 Jan 8.
3
Health Care Costs After Genome-Wide Sequencing for Children With Rare Diseases in England and Canada.英国和加拿大对罕见病儿童进行全基因组测序后的医疗费用。
JAMA Netw Open. 2024 Jul 1;7(7):e2420842. doi: 10.1001/jamanetworkopen.2024.20842.
4
Genetics of liver disease in adults.成人肝脏疾病的遗传学。
Hepatol Commun. 2024 Mar 29;8(4). doi: 10.1097/HC9.0000000000000408. eCollection 2024 Apr 1.
5
Physician services and costs after disclosure of diagnostic sequencing results in the NYCKidSeq program.公布 NYCKidSeq 项目诊断测序结果后的医师服务和费用。
Genet Med. 2024 Jan;26(1):101011. doi: 10.1016/j.gim.2023.101011. Epub 2023 Oct 27.
6
Exome/Genome Sequencing in Undiagnosed Syndromes.外显子组/基因组测序在未确诊综合征中的应用。
Annu Rev Med. 2023 Jan 27;74:489-502. doi: 10.1146/annurev-med-042921-110721.
7
Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation.在罕见病的诊断途径中定位全外显子组测序以优化其效用:一项观察性队列研究和经济评估的方案。
BMJ Open. 2022 Oct 10;12(10):e061468. doi: 10.1136/bmjopen-2022-061468.
8
Ethical Considerations for Equitable Access to Genomic Sequencing for Critically Ill Neonates in the United States.美国危重新生儿公平获取基因组测序的伦理考量
Int J Neonatal Screen. 2022 Mar 21;8(1):22. doi: 10.3390/ijns8010022.
9
Cost Efficacy of Rapid Whole Genome Sequencing in the Pediatric Intensive Care Unit.儿科重症监护病房中快速全基因组测序的成本效益
Front Pediatr. 2022 Jan 24;9:809536. doi: 10.3389/fped.2021.809536. eCollection 2021.
10
A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders.对单基因疾病遗传筛查和检测的经济评估方法学质量的系统评价。
Genet Med. 2022 Feb;24(2):262-288. doi: 10.1016/j.gim.2021.10.008. Epub 2021 Dec 7.

本文引用的文献

1
Genome sequencing as a platform for pharmacogenetic genotyping: a pediatric cohort study.作为药物遗传学基因分型平台的基因组测序:一项儿科队列研究。
NPJ Genom Med. 2017 May 26;2:19. doi: 10.1038/s41525-017-0021-8. eCollection 2017.
2
Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions.全外显子组测序对疑似单基因疾病的门诊儿童的诊断影响及成本效益
JAMA Pediatr. 2017 Sep 1;171(9):855-862. doi: 10.1001/jamapediatrics.2017.1755.
3
Whole Genome Sequencing Expands Diagnostic Utility and Improves Clinical Management in Pediatric Medicine.全基因组测序扩大了诊断效用并改善了儿科医学的临床管理。
NPJ Genom Med. 2016 Jan 13;1:15012-. doi: 10.1038/npjgenmed.2015.12.
4
A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder.自闭症谱系障碍临床基因组检测策略的微成本和成本后果分析。
Genet Med. 2017 Nov;19(11):1268-1275. doi: 10.1038/gim.2017.47. Epub 2017 May 4.
5
Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy.基因组医学中的检测定价与报销:迈向通用策略
Public Health Genomics. 2016;19(6):352-363. doi: 10.1159/000449152. Epub 2016 Sep 28.
6
Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine.口腔健康与系统医学中精准生物标志物的早期健康技术评估
OMICS. 2016 Jan;20(1):30-5. doi: 10.1089/omi.2015.0174.
7
Assessing the Costs and Cost-Effectiveness of Genomic Sequencing.评估基因组测序的成本及成本效益
J Pers Med. 2015 Dec 10;5(4):470-86. doi: 10.3390/jpm5040470.
8
Costs of the diagnostic odyssey in children with inherited leukodystrophies.患有遗传性脑白质营养不良症儿童诊断过程中的花费
Neurology. 2015 Sep 29;85(13):1167-70. doi: 10.1212/WNL.0000000000001974. Epub 2015 Aug 28.
9
The SickKids Genome Clinic: developing and evaluating a pediatric model for individualized genomic medicine.病童基因组诊所:开发和评估个性化基因组医学的儿科模式。
Clin Genet. 2016 Jan;89(1):10-9. doi: 10.1111/cge.12579. Epub 2015 Mar 24.
10
Clinical utility of genetic and genomic services: a position statement of the American College of Medical Genetics and Genomics.基因和基因组服务的临床实用性:美国医学遗传学与基因组学学会的立场声明。
Genet Med. 2015 Jun;17(6):505-7. doi: 10.1038/gim.2015.41. Epub 2015 Mar 12.